Allakos Inc. (ALLK) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Allakos Inc. (ALLK) trades at $0.3291 with AI Score 47/100 (Grade C). Allakos Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for allergy, inflammatory, and proliferative diseases. Market cap: $29.7M, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for ALLK: ALLK does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALLK against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALLK: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Allakos Inc. (ALLK) Healthcare & Pipeline Overview
Allakos Inc. is a clinical-stage biopharmaceutical company specializing in therapeutics for allergy, inflammatory, and proliferative diseases. Its lead product, lirentelimab (AK002), targets immunomodulatory receptors and is currently in Phase III trials for eosinophilic gastritis/duodenitis and Phase II/III trials for eosinophilic esophagitis, positioning the company within the competitive biotechnology landscape.
What Is the Investment Thesis for ALLK?
Allakos Inc. presents a high-risk, high-reward investment opportunity characteristic of clinical-stage biopharmaceutical companies. The primary value driver is the successful development and commercialization of lirentelimab (AK002). Positive results from the ongoing Phase III study for eosinophilic gastritis/duodenitis and the Phase II/III study for eosinophilic esophagitis are critical catalysts. A gross margin of 50.0% suggests potential profitability upon commercialization, but the company's negative profit margin of -663.4% highlights its current reliance on external funding. Key risks include clinical trial failures, regulatory hurdles, and the need for additional capital. The company's low beta of 0.14 indicates lower volatility compared to the broader market, but this does not mitigate the inherent risks associated with biotechnology investments. The company's market capitalization is $0.03B as of 2026-05-10.
Based on FMP financials and quantitative analysis
ALLK Key Highlights
- Lirentelimab (AK002) is in Phase III study for eosinophilic gastritis and/or eosinophilic duodenitis.
- Lirentelimab (AK002) is in Phase II/III study for eosinophilic esophagitis.
- Gross Margin of 50.0% indicates potential profitability upon commercialization.
- Market Cap of $29.7M as of 2026-05-10 reflects its current valuation.
- Profit Margin of -663.4% highlights reliance on external funding.
Who Are ALLK's Competitors?
ALLK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLRX BioLineRx Ltd. | $2.92 | +3.18% | $12.7M | 69 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | -9.09% | $7.95M | 72 |
| ORMP Oramed Pharmaceuticals Inc. | $4.02 | -1.95% | $165M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALLK's Key Strengths?
- Lead product lirentelimab (AK002) in Phase III trials.
- Focus on unmet medical needs in allergy and inflammatory diseases.
- Proprietary technology targeting immunomodulatory receptors.
- Experienced management team in drug development.
What Are ALLK's Weaknesses?
- Clinical-stage company with no approved products.
- High reliance on the success of lirentelimab.
- Negative profit margin and reliance on external funding.
- Limited financial resources compared to larger pharmaceutical companies.
What Could Drive ALLK Stock Higher?
- Data readout from Phase III study of lirentelimab for eosinophilic gastritis/duodenitis.
- Data readout from Phase II/III study of lirentelimab for eosinophilic esophagitis.
- Enrollment and progress in Phase II clinical study of lirentelimab for atopic dermatitis and chronic spontaneous urticaria.
- Development and advancement of AK006 for allergic and inflammatory diseases.
What Are the Key Risks for ALLK?
- Financial-distress signal — its Altman Z-Score of -29.64 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-38.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays for lirentelimab and AK006.
- Regulatory hurdles and delays in obtaining FDA approval.
- Competition from other companies developing similar therapies.
- Dependence on external funding to support clinical development.
- Patent challenges and intellectual property disputes.
What Are the Growth Opportunities for ALLK?
- Expansion into Atopic Dermatitis and Chronic Spontaneous Urticaria: Allakos is currently conducting a Phase II clinical study of lirentelimab for atopic dermatitis and chronic spontaneous urticaria. Positive results could open up a significant market opportunity, as these conditions affect millions worldwide. The atopic dermatitis market is projected to reach $16.4 billion by 2027, while the chronic spontaneous urticaria market is expected to reach $3.7 billion by 2028. Successful trials and subsequent commercialization could significantly increase Allakos's revenue streams.
- Development of AK006 for Allergic and Inflammatory Diseases: Allakos is developing AK006 to treat allergic and inflammatory diseases, expanding its pipeline beyond lirentelimab. The market for allergic and inflammatory disease treatments is substantial and growing, driven by increasing prevalence and unmet medical needs. Successful development and commercialization of AK006 could diversify Allakos's product portfolio and reduce its reliance on lirentelimab. The global inflammatory disease market is projected to reach $127.7 billion by 2028.
- Treatment of Mast Cell Gastrointestinal Disease: Allakos is exploring the potential of lirentelimab for treating mast cell gastrointestinal disease. This represents a significant growth opportunity, as there are limited treatment options available for these conditions. Successful development and commercialization of lirentelimab for mast cell gastrointestinal disease could establish Allakos as a leader in this niche market. The market size for mast cell disorders is expected to grow as diagnostic capabilities improve and awareness increases.
- Treatment of Severe Allergic Conjunctivitis: Allakos is developing lirentelimab for the treatment of severe allergic conjunctivitis. This condition affects a significant portion of the population and can significantly impact quality of life. The allergic conjunctivitis market is expected to grow, driven by increasing prevalence and the development of new therapies. Successful development and commercialization of lirentelimab for severe allergic conjunctivitis could provide Allakos with a valuable revenue stream. The global allergic conjunctivitis market is projected to reach $3.1 billion by 2027.
- Treatment of Indolent Systemic Mastocytosis: Allakos is also exploring the potential of lirentelimab for the treatment of indolent systemic mastocytosis. This rare disease represents an unmet medical need, and successful development and commercialization of lirentelimab could provide Allakos with a first-in-class therapy. The market for indolent systemic mastocytosis is expected to grow as diagnostic capabilities improve and awareness increases. While the market size is relatively small, the potential for orphan drug designation and premium pricing could make this a valuable opportunity for Allakos.
What Opportunities Does ALLK Have?
- Positive clinical trial results for lirentelimab.
- Expansion into new indications and markets.
- Partnerships with larger pharmaceutical companies.
- Potential for orphan drug designation for rare diseases.
What Threats Does ALLK Face?
- Clinical trial failures or delays.
- Regulatory hurdles and delays in approval.
- Competition from other companies developing similar therapies.
- Patent challenges and intellectual property disputes.
What Are ALLK's Competitive Advantages?
- Patented lirentelimab (AK002) provides exclusivity.
- Clinical trial data demonstrating efficacy and safety.
- Focus on specific immunomodulatory receptors.
- Expertise in developing monoclonal antibody therapeutics.
What Does ALLK Do?
Allakos Inc., incorporated in 2012 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company dedicated to developing therapeutics that target immunomodulatory receptors present on immune effector cells. These therapeutics aim to address allergy, inflammatory, and proliferative diseases. The company's primary focus is on its lead monoclonal antibody, lirentelimab (AK002), which is designed to inhibit Siglec-8, an inhibitory receptor selectively expressed on eosinophils and mast cells. Lirentelimab is currently undergoing several clinical trials. These include a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis, a Phase II/III study for eosinophilic esophagitis, and a Phase II clinical study for atopic dermatitis and chronic spontaneous urticaria. Allakos is also exploring the potential of lirentelimab for treating mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. In addition to lirentelimab, Allakos is developing AK006 to treat allergic and inflammatory diseases, further expanding its therapeutic pipeline. The company operates with a team of 131 employees, managing the development and clinical trials of its therapeutic candidates.
What Products and Services Does ALLK Offer?
- Develops therapeutics targeting immunomodulatory receptors.
- Focuses on treatments for allergy, inflammatory, and proliferative diseases.
- Lead product is lirentelimab (AK002), a monoclonal antibody.
- Conducts clinical trials for eosinophilic gastritis/duodenitis, eosinophilic esophagitis, atopic dermatitis, and chronic spontaneous urticaria.
- Develops AK006 for allergic and inflammatory diseases.
- Explores treatments for mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis.
How Does ALLK Make Money?
- Develops and patents novel therapeutic antibodies.
- Conducts preclinical and clinical trials to evaluate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Aims to commercialize approved therapies through partnerships or direct sales.
What Industry Does ALLK Operate In?
Allakos operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The company focuses on developing treatments for allergy, inflammatory, and proliferative diseases, addressing a market with substantial unmet needs. Competition includes established pharmaceutical companies and other biotechnology firms developing similar therapies. The success of Allakos depends on its ability to navigate the complex regulatory landscape and demonstrate the efficacy and safety of its drug candidates in clinical trials. The biotechnology industry is experiencing growth driven by advancements in genomics, proteomics, and personalized medicine.
Who Are ALLK's Key Customers?
- Patients suffering from eosinophilic gastritis/duodenitis.
- Patients suffering from eosinophilic esophagitis.
- Patients suffering from atopic dermatitis.
- Patients suffering from chronic spontaneous urticaria.
Net sellingInsider Activity
The most recent 12 insider filings for Allakos Inc. break down as 12 sales and 0 purchases. On net that is roughly 6.2M shares disposed (about $12.8M), a signal worth weighing alongside the fundamentals.
FY2026 estForward Outlook
Wall Street analysts project Allakos Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.33.
F-Score 1/9Financial Health
Allakos Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -29.64 places it in the distress zone, a signal of elevated financial risk.
ROE -38%Key Financial Metrics
Return on equity for Allakos Inc. stands at -38.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -43.3%, showing how much profit it generates from its asset base. A current ratio of 14.23 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -87.2%, the inverse of the P/E and a quick read on earnings relative to price.
Allakos Inc. (ALLK) Valuation Context
Valued at $29.7M, ALLK is classified as a micro-cap stock. Relative to its peer group, ALLK's quantitative score of 47/100 is below the peer average of 73/100.
Company Profile
Allakos Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Carlos, US. The company is led by CEO Robert Alexander. ALLK has traded publicly since 2018.
ALLK Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Lead product lirentelimab (AK002) in Phase III trials.
- Focus on unmet medical needs in allergy and inflammatory diseases.
- Proprietary technology targeting immunomodulatory receptors.
- Experienced management team in drug development.
Bear Case
- Clinical-stage company with no approved products.
- High reliance on the success of lirentelimab.
- Negative profit margin and reliance on external funding.
- Limited financial resources compared to larger pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $4M | $376,000 | $0.0042 |
Based on FMP financials and quantitative analysis
ALLK Latest News
No recent news available for ALLK.
ALLK Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALLK.
Price Targets
Wall Street price target analysis for ALLK.
ALLK MoonshotScore
What does this score mean?
The MoonshotScore rates ALLK 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Robert Alexander
CEO
Robert Alexander serves as the CEO of Allakos Inc., managing a team of 131 employees. His background includes extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. He has held leadership positions at various biotechnology companies, contributing to the advancement of novel therapeutics. Alexander's expertise spans across multiple therapeutic areas, including allergy, inflammation, and immunology. His educational credentials include advanced degrees in science and business, providing a strong foundation for his role at Allakos.
Track Record: Under Robert Alexander's leadership, Allakos Inc. has advanced lirentelimab (AK002) through multiple clinical trials, including Phase III studies. He has overseen the expansion of the company's pipeline and the development of AK006. Key milestones include securing funding for clinical trials and establishing partnerships with research institutions. Alexander has focused on building a strong team and fostering a culture of innovation within the company.
Common Questions About ALLK (Healthcare)
What does the AI Score mean for ALLK?
ALLK holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Allakos Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for allergy, inflammatory, and proliferative diseases. Their lead monoclonal antibody, lirentelimab …
What does Allakos Inc. do?
Allakos Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for allergy, inflammatory, and proliferative diseases. The company's lead product, lirentelimab (AK002), is a monoclonal antibody targeting Siglec-8, an inhibitory receptor selectively expressed on eosinophils and mast cells. Allakos is conducting clinical trials for lirentelimab in various indications, including eosinophilic gastritis/duodenitis, eosinophilic esophagitis, atopic dermatitis, and chronic spontaneous urticaria.
What do analysts say about ALLK stock?
Analyst coverage of Allakos Inc. is limited, reflecting its status as a clinical-stage biopharmaceutical company with no approved products. Current analyst sentiment is cautiously optimistic, with a focus on the potential of lirentelimab (AK002) in treating eosinophilic diseases. Key valuation metrics are difficult to assess due to the company's lack of revenue and profitability.
What are the main risks for ALLK?
The main risks for Allakos Inc. are typical of clinical-stage biopharmaceutical companies. These include the risk of clinical trial failures or delays, which could significantly impact the company's valuation and future prospects. Regulatory hurdles and delays in obtaining FDA approval represent another significant risk. Competition from other companies developing similar therapies could also limit Allakos's market share.
What are the key factors to evaluate for ALLK?
Allakos Inc. (ALLK) holds an AI score of 47/100 (low). Not financial advice.
How frequently does ALLK data refresh on this page?
ALLK's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ALLK's recent stock price performance?
Allakos Inc. (ALLK) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product lirentelimab (AK002) in Phase III trials. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALLK overvalued or undervalued right now?
Allakos Inc. (ALLK) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ALLK before investing?
Before investing in Allakos Inc. (ALLK), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual risk tolerance and financial situation.